Published online before print May 8, 2009, doi: 10.1161/CIRCHEARTFAILURE.108.812099
Original Articles |
Control by Circulating Factors of Mitochondrial Function and Transcription Cascade in Heart Failure
A Role for Endothelin-1 and Angiotensin II
From the INSERM (A.G., D.F., F.L., V.V., R.V.C.), U-769, Châtenay-Malabry, France; Univ Paris-Sud (A.G., D.F., F.L., V.V., R.V.C.), IFR 141, Châtenay-Malabry, France; and Département de Physiologie (J.Z., B.N., B.G., B.M.), CHRU, EA3072, Strasbourg, France.
Correspondence to Anne Garnier, PhD, INSERM, U-769, Université Paris Sud, 5 rue Jean-Baptiste Clément, F-92296 Châtenay-Malabry, France. E-mail anne.garnier{at}u-psud.fr
Received August 11, 2008; accepted March 12, 2009.
Background— Evidence is emerging to support the concept that the failing heart is "energy depleted" and that defects in energy metabolism are important determinants in the development and the progression of the disease. We have shown previously that depressed mitochondrial function in cardiac and skeletal muscles in chronic heart failure is linked to decreased expression of the gene encoding transcriptional proliferator-activated receptor-
coactivator-1
, the inducible regulator of mitochondrial biogenesis and its transcription cascade, leading to altered expression of mitochondrial proteins. However, oxidative capacity of the myocardium of patients treated for chronic heart failure and pathophysiological mechanisms of mitochondrial dysfunction are still largely unknown.
Methods and Results— In patients with chronic heart failure treated with angiotensin-converting enzyme inhibition, cardiac oxidative capacity, measured in saponin-permeabilized fibers, was 25% lower, and proliferator-activated receptor- coactivator-1 protein content was 34% lower compared with nonfailing controls. In a rat model of myocardial infarction, angiotensin-converting enzyme inhibition therapy was only partially able to protect cardiac mitochondrial function and transcription cascade. Expression of proliferator-activated receptor- coactivator-1 and its transcription cascade were evaluated after a 48-hour exposure of cultured adult rat ventricular myocytes to endothelin-1, angiotensin II, aldosterone, phenylephrine, or isoprenaline. Endothelin-1 (–30%) and, to a lesser degree, angiotensin II (–20%) decreased proliferator-activated receptor- coactivator-1 mRNA content, whereas other hormones had no effect (phenylephrine) or even increased it (aldosterone, isoprenaline).
Conclusions— Taken together, these results show that, despite angiotensin-converting enzyme inhibition treatment, oxidative capacity is reduced in human and experimental heart failure and that endothelin-1 and angiotensin II could be involved in the downregulation of the mitochondrial transcription cascade.
Key Words: angiotensin II • endothelin-1 • mitochondrial biogenesis • heart failure • proliferator-activated receptor- coactivator-1
CLINICAL PERSPECTIVE
Related Article
- On the Control of Metabolic Remodeling in Mitochondria of the Failing Heart
- Joanne S. Ingwall
Circ Heart Fail 2009 2: 275-277.[Extract] [Full Text] [PDF]